Inflammation in the genesis and perpetuation of atrial fibrillation

European Heart Journal

Volumn 26, Issue 20, 2005, Pages 2083-2092

  Engelmann, Mads D M ^a   Svendsen, Jesper Hastrup ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Atrial fibrillation; C reactive protein; Glucocorticoid; Inflammation; Statin

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ASCORBIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; IRBESARTAN; METHYLPREDNISOLONE; PRAVASTATIN; SIMVASTATIN; TRANDOLAPRIL; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVERSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; EPIDEMIOLOGICAL DATA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INFLAMMATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTROPHYSIOLOGY; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM;

EID: 26044478131     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi350     Document Type: Review

References (73)

1. Nattel S, Li D, Yue L. Basic mechanisms of atrial fibrillation-very new insights into very old ideas. Annu Rev Physiol 2000;62:51-77.
2. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-1184.
4. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, Yutani C, Ohe T. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003;111:137-142.
5. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-111.
6. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
8. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005;98:1154-1162.
9. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148-1150.
10. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC Jr, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation). Developed in collaboration with the North American society of pacing and electrophysiology. Circulation 2001;104:2118-2150.
11. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
12. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-3010.
13. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-180.
14. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96: 3542-3548.
15. del Balzo U, Polley MJ, Levi R. Cardiac anaphylaxis. Complement activation as an amplification system. Circ Res 1989;65:847-857.
16. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
17. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-1107.
18. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol 2004;93:1176-1178.
19. Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A, Possati G. The - 174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003;108:195-199.
20. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003;9:RA225-RA229.
21. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-2891.
22. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001;56:375-380.
23. Conway DSG, Buggins P, Hughes E, Lip GYH. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004;94:508-510.
24. Maycock CAA, Lappé DL, Crandall BG, Muhlestein JB, Horne BD, Bair TL, Li Q, Reyna SP, Renlund DG, Anderson JL. Is atrial fibrillation an inflammatory disease reflected by elevated C-reactive protein? J Am Coll Cardiol 2003;41 (Suppl. A):99A.
25. Asselbergs FW, Diercks GF, van den Berg MP, van Boven AJ, Van Gelder IC, van Veldhuisen DJ, van Gilst WH. C-reactive protein and microalbunminuria are associated with atrial fibrillation. J Am Coll Cardiol 2003;41:99A.
26. Sanchez PL, Pabon P, Moriñigo JL, Ledesma C, Martin F, Collado JR, Cascon M, Martin-Luengo C. Do baseline C-reactive protein levels predict the new-onset of atrial fibrillation in patients with acute coronary syndrome? Eur Heart J 2003;24:509.
27. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, Miyahara K. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004; 45:441-445.
28. Acevedo M, Cobalan RL, Perez L, Brayun S, Pereira J, Lira T, Navarrete C. C-reactive protein in atrial fibrillation: evidence for the presence of inflammation in the genesis and perpetuation of the arrhythmia. J Am Coll Cardiol 2003;41:1089.
29. Goldstein RN, Khrestian C, Ryu K, Popoy M, Lamorgese M, Waldo AL, Van Wagoner DR. CRP levels predicts arrhythmia inducibility and neutrophil infiltration in the canine sterile model. (Abstract). Circulation 2003;108:323, 1522 Suppl. S.
30. Lip G. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-1314.
31. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
32. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
33. Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 2003;108:2317-2322.
34. Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F, Lip GY. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003;24:1373-1380.
35. Conway DSG, Buggins P, Hughes E, Lip GYH. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004;43:2075-2082.
36. Conway DSG, Buggins P, Hughes E, Lip GYH. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004;93:1368-1373.
37. Conway DSG, Buggins P, Hughes E, Lip GYH. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004;148:462-466.
38. Roldan V, Marin F, Martinez JG, Garcia-Herola A, Sogorb F, Lip GYH. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005;95:881-882.
39. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis of adrenocortical hormones. In: Hardman JG, Limbird LE, eds. Goodman and Gliman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996. p1459-1485.
40. Chaney MA, Nikolov MP, Blakeman B, Bakhos M, Slogoff S. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 1998;87:27-33.
41. McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 1993;104:622-623.
42. Ueda N, Yoshikawa T, Chihara M, Kawaguchi S, Niinomi Y, Yasaki T. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol 1988;2:29-31.
43. Yared JP, Starr NJ, Torres FK, Bashour CA, Bourdakos G, Piedmonte M, Michener JA, Davis JA, Rosenberger TE. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 2000;69:1420-1424.
44. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.
45. Sacks FM. High-intensity statin treatment for coronary heart disease. JAMA 2004;291:1132-1134.
46. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109:11-18.
47. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 2003;10:140-144.
48. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmunity Reviews 2003;2:332-338.
49. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
50. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001;154:87-96.
51. Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 2003;93:697-699.
52. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002;53:911-920.
53. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive c-reactive protein levels. Circulation 2001;103:1933-1935.
54. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AFH, Kastelein JJP. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002;165:361-366.
55. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080.
56. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-843.
57. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-2319.
58. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345.
59. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383.
60. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-782.
61. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
62. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608-2614.
63. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60:315-325.
64. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
65. Madrid AH, Bueno MG, Rebollo J, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: prospective and randomized study. Circulation 2002;106:331-336.
66. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-2098.
67. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931.
68. Anne W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbuchel H. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 2004;90: 1025-1030.
69. Madrid AH, Peng J, Zamora J, Marin I, Bernal E, Escobar C, Munos-Tinoco C, Rebollo J, Moro C. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. PACE 2004;27:1405-1410.
70. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Ubago J, Diez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-291.
71. Madrid AH, Escobar C, Rebollo J, Bernal I, Nannini S, Limón L, Peng J, Moro C. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Cardiac Electrophysiol Rev 2003;7:243-246.
72. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266.
73. Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure-five more years. N Engl J Med 2004;351:2437-2440.